{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:19:44Z","timestamp":1787015984957,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Verdinexor (Laverdia\u2010CA1; Dechra Veterinary Products), a selective inhibitor of nuclear export, has been utilised for treatment of non\u2010Hodgkin T\u2010cell lymphoma in dogs. However, the efficacy of verdinexor has not been evaluated for cutaneous epitheliotropic T\u2010cell lymphoma (CETL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy of verdinexor for the treatment of CETL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Eight client\u2010owned animals with CETL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Patients received between 1.28 and 1.45\u2009mg\/kg verdinexor per os twice weekly with a minimum of 72\u2009h between doses until disease progression or voluntary withdrawal. Adjunctive therapy with lokivetmab or prednisone was permitted after Day (D)14. Assessment of clinical lesions (canine Response Evaluation Criteria in Solid Tumors [cRECIST v1.0] and novel Canine Epitheliotropic Lymphoma Extent and Severity Index [CELESI]), pruritus (Visual Analog Scale) and treatment efficacy (owner global assessment of treatment efficacy [OGATE]) were evaluated every 14\u2009days for 3\u2009months, then monthly thereafter (mean 70\u2009\u00b1\u200943.4\u2009days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010five percent of patients achieved complete response, partial response or stable disease. The mean time to disease progression was 56\u2009\u00b1\u200941\u2009days. There was a significant reduction (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026) in total CELESI score when the lowest score for each dog was compared to their score at D0. Verdinexor did not significantly reduce pruritus at any time point (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.45), including when given as a monotherapy or concurrently with lokivetmab \u00b1 glucocorticoids. On D28, 75% of owners rated response to treatment as \u2018fair\u2019 to \u2018excellent\u2019. The most common adverse effects included weight loss, inappetence, vomiting and lethargy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Relevance<\/jats:title>\n                    <jats:p>Verdinexor could be considered a safe, palliative treatment for canine CETL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vde.13280","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T20:00:37Z","timestamp":1722283237000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of verdinexor for the treatment of na\u00efve canine epitheliotropic cutaneous T\u2010cell lymphoma: An open\u2010label pilot study"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8302-5731","authenticated-orcid":false,"given":"Elana M.","family":"Vlodaver","sequence":"first","affiliation":[{"name":"Animal Dermatology Group Inc  Tustin California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kelly","family":"Keating","sequence":"additional","affiliation":[{"name":"Animal Dermatology Group Inc  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie A.","family":"Bidot","sequence":"additional","affiliation":[{"name":"Office of Animal Resources Western University of Health Sciences  Pomona California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Bruyette","sequence":"additional","affiliation":[{"name":"Anivive Lifesciences  Long Beach California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1616-8261","authenticated-orcid":false,"given":"Wayne S.","family":"Rosenkrantz","sequence":"additional","affiliation":[{"name":"Animal Dermatology Group Inc  Tustin California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2008.00176.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00814.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/03009858221140818"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-165X.1997.tb00735.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/030098588402100209"},{"key":"e_1_2_10_7_1","first-page":"421","article-title":"Canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T cells","volume":"144","author":"Moore PF","year":"1994","journal-title":"Am J Pathol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2018.08.007"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962012000600001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.240"},{"key":"e_1_2_10_11_1","article-title":"Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003\u20132015)","volume":"29","author":"Chan CM","year":"2017","journal-title":"Vet Dermatol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb00756.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12430"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12318"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1587-9"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb02833.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2007.00616.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1569-y"},{"issue":"2","key":"e_1_2_10_20_1","first-page":"439","article-title":"Response assessment in neuro\u2010oncology clinical trials","volume":"35","author":"Wen PY","year":"2017","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.0344"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.13123"},{"key":"e_1_2_10_23_1","unstructured":"McMahonR.Safety evaluation of verdinexor in combination with lomustine in dogs with relapsed multicentric lymphoma. Resident oral abstracts. Presented at veterinary cancer society annual conference Reno NV USA.2023."}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.13280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:36:41Z","timestamp":1734593801000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.13280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/vde.13280"],"URL":"https:\/\/doi.org\/10.1111\/vde.13280","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"2024-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}